Hormone therapy dosing study for metastatic prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 years or older.
- You have prostate cancer that has spread and is hormone-sensitive or has become resistant to hormone therapy, and your doctor plans to give you a new hormone medicine plus standard hormone therapy.
- If you have already had hormone therapy, you must have started it less than 12 weeks ago (or, if it was after surgery, you finished it more than a year ago).
- You are generally well enough to be active or up and about (ECOG 0-2).
- You must not have other untreated cancers or serious heart or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This study tests whether a shorter course of a newer hormone pill (apalutamide or enzalutamide) works well for men whose prostate cancer has spread to just a few spots and who recently started standard hormone therapy. It may allow you to take medication for less time while still controlling the cancer.
This trial studies whether taking hormone therapy in breaks (instead of continuously) can work for people with metastatic prostate cancer whose PSA is very low after prior treatment with hormone-deprivation plus an AR pathway inhibitor. It may help reduce time on treatment while still keeping cancer controlled.
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This trial tests a new way to predict how well hormone therapy combined with newer drugs works for men with prostate cancer that has spread. It uses advanced tissue analysis to help tailor treatment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.